Business Context and Reporting Period
This Form 8-K Current Report was filed by Protagonist Therapeutics, Inc. on May 16, 2018, regarding events occurring on May 15, 2018. The Company is a Delaware corporation and an emerging growth company. The filing addresses corporate governance changes, specifically the appointment of a new director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Cash Compensation: $40,000 for Board service, paid in quarterly installments.
- Initial Stock Option Grant: 24,000 shares with an exercise price of $6.45 per share.
- Future Annual Option Grant Eligibility: 12,000 shares per year.
Material Changes
The primary material change reported is the expansion of the Board of Directors:
- Director Appointment: Bryan Giraudo was appointed as a Class III director effective May 15, 2018.
- Independence: The Board determined Mr. Giraudo is an independent director under Nasdaq standards.
- Board Size: The number of authorized directors was increased from seven to eight.
- Committee Assignments: No committee assignments were determined at the time of filing.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No specific risks or contingencies were disclosed in this report. The document notes that Mr. Giraudo will enter into a standard indemnification agreement consistent with other directors.
Investor Verification Checklist
- Verify the vesting schedule of the 24,000 initial stock options (36 equal monthly installments).
- Confirm the exercise price of $6.45 per share against the closing price on May 15, 2018.
- Monitor future filings for Mr. Giraudo's specific committee assignments and any associated additional compensation.
- Review the Company's Non-Employee Director Compensation Policy for details on future annual grants.